Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
United States
/
Pharmaceuticals & Biotech
Create a narrative
Madrigal Pharmaceuticals Community
NasdaqGS:MDGL Community
1
Narratives
written by author
0
Comments
on narratives written by author
15
Fair Values set
on narratives written by author
Community Investing Ideas
Madrigal Pharmaceuticals
Popular
Undervalued
Overvalued
Madrigal Pharmaceuticals
AN
AnalystConsensusTarget
Consensus Narrative from 14 Analysts
US Patent And EU Expansion Will Secure Future Potential
Key Takeaways Decades of patent protection and growing disease prevalence position Rezdiffra for sustained revenue growth, market expansion, and pricing power. International launches, pipeline diversification, and solid financial resources reduce risk and support expansion into new markets and indications.
View narrative
US$438.43
FV
21.1% undervalued
intrinsic discount
69.23%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
6
users have followed this narrative
3 days ago
author updated this narrative
Your Valuation for
MDGL
MDGL
Madrigal Pharmaceuticals
Your Fair Value
US$
Current Price
US$345.73
18.4% undervalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
-510m
2b
2015
2018
2021
2024
2025
2027
2030
Revenue US$2.5b
Earnings US$507.5m
Advanced
Set Fair Value